VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2021 | 90Y-FF-21101: a P-cadherin-targeting antibody in advanced CRC

Vivek Subbiah, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the results of a Phase I expansion study of 90Y-FF-21101, a P-cadherin targeting monoclonal antibody in advanced chemorefractory colorectal (CRC) and pancreatic-biliary cancers. Overexpression of the cell-cell adhesion protein P-cadherin has been associated with a more aggressive cancer cell phenotype, cancer stem cell properties, tumor invasion, and metastasis and therefore may prove an important target for therapy in advanced colorectal and pancreatic-biliary cancers. This novel antibody was well-tolerated and preliminary evidence suggests clinical benefit in heavily pre-treated patients with advanced colorectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter